ARTV vs NKTR vs FATE vs ALNY

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus -99. 3% for Artiva Biotherapeutics, Inc. (ARTV). Alnylam Pharmaceuticals, Inc. (ALNY) offers the better valuation at 127. 0x trailing P/E (44. 2x forward), making it the more compelling value choice. Analysts rate Artiva Biotherapeutics, Inc. (ARTV) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +125. 4%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: ALNY returned +411. 9% versus NKTR's -59. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.

(ALNY) is the lower-risk stock at 0. 71β versus Artiva Biotherapeutics, Inc. 's 2. 27β — meaning ARTV is approximately 221% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Artiva Biotherapeutics, Inc. (ARTV) carries a lower debt/equity ratio of 8% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus -99. 3% for Artiva Biotherapeutics, Inc. (ARTV). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -337. 0% for Artiva Biotherapeutics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alnylam Pharmaceuticals, Inc.

(ALNY) is the more profitable company, earning 8. 4% net margin versus -233. 0% for Artiva Biotherapeutics, Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13. 5% versus -268. 1% for ARTV. At the gross margin level — before operating expenses — ARTV leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 1525.

5% to $39. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +411. 9% 10Y return). Artiva Biotherapeutics, Inc. (ARTV) carries a higher beta of 2. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +411. 9%, ARTV: +4. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARTV is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock; ALNY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.